Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

JJC8-088

From Wikipedia, the free encyclopedia
Cocaine-like dopamine reuptake inhibitor derived from modafinil
Pharmaceutical compound
JJC8-088
Clinical data
Drug classTypicaldopamine reuptake inhibitor
Identifiers
  • 1-[4-[2-[bis(4-fluorophenyl)methylsulfinyl]ethyl]piperazin-1-yl]-3-phenylpropan-2-ol
CAS Number
PubChemCID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC28H32F2N2O2S
Molar mass498.63 g·mol−1
3D model (JSmol)
  • C1CN(CCN1CCS(=O)C(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)CC(CC4=CC=CC=C4)O
  • InChI=1S/C28H32F2N2O2S/c29-25-10-6-23(7-11-25)28(24-8-12-26(30)13-9-24)35(34)19-18-31-14-16-32(17-15-31)21-27(33)20-22-4-2-1-3-5-22/h1-13,27-28,33H,14-21H2
  • Key:MACFTPBZAOCTFN-UHFFFAOYSA-N

JJC8-088 is adopamine reuptake inhibitor (DRI) that wasderived from thewakefulness-promoting agentmodafinil.[1][2][3]

It has substantially higheraffinity for thedopamine transporter (DAT) than modafinil (Ki = 6.72 nM vs. 2,600 nM; 387-fold).[2] In contrast to modafinil and otheranalogues, which are atypical DRIs, JJC8-088 is a typicalcocaine-like DRI.[1][3] It haspotent cocaine-likepsychostimulant effects, produces robust anddose-dependent increases indopamine levels in thenucleus accumbens, and is readilyself-administered by and substitutes for cocaine in animals.[1][3]

Similarly to cocaine, but unlike modafinil and other analogues, JJC8-088 stabilizes the DAT in an outward-facing open conformation.[1] It has been theorized that cocaine-like DRIs may actually act asdopamine releasing agent-like DAT "inverse agonists" rather than as simpletransporter blockers.[4]

In addition to its affinity for the DAT, JJC8-088 has low affinity for theserotonin transporter (SERT) (Ki = 213 nM; 32-fold less than for the DAT) and for thenorepinephrine transporter (NET) (Ki = 1950 nM; 290-fold less than for the DAT).[2] It also binds with high affinity to thesigmaσ1 receptor (Ki = 41.6 nM).[5]

The drug has high affinity for thehERGantitarget (IC50Tooltip half-maximal inhibitory concentration = 130 nM) and could producecardiotoxicity,[6][7] which might cause a risk ofheart attack if JJC8-088 were to be used recreationally.[8][9]

See also

[edit]

References

[edit]
  1. ^abcdTanda G, Hersey M, Hempel B, Xi ZX, Newman AH (February 2021)."Modafinil and its structural analogs as atypical dopamine uptake inhibitors and potential medications for psychostimulant use disorder".Current Opinion in Pharmacology.56:13–21.doi:10.1016/j.coph.2020.07.007.PMC 8247144.PMID 32927246.
  2. ^abcAggarwal S, Mortensen OV (2023). "Discovery and Development of Monoamine Transporter Ligands".Drug Development in Psychiatry. Advances in Neurobiology. Vol. 30. pp. 101–129.doi:10.1007/978-3-031-21054-9_4.ISBN 978-3-031-21053-2.PMC 10074400.PMID 36928847.
  3. ^abcHersey M, Bacon AK, Bailey LG, Coggiano MA, Newman AH, Leggio L, Tanda G (2021)."Psychostimulant Use Disorder, an Unmet Therapeutic Goal: Can Modafinil Narrow the Gap?".Frontiers in Neuroscience.15 656475.doi:10.3389/fnins.2021.656475.PMC 8187604.PMID 34121988.
  4. ^Heal DJ, Gosden J, Smith SL (December 2014). "Dopamine reuptake transporter (DAT) "inverse agonism"--a novel hypothesis to explain the enigmatic pharmacology of cocaine".Neuropharmacology.87:19–40.doi:10.1016/j.neuropharm.2014.06.012.PMID 24953830.
  5. ^Newman AH, Ku T, Jordan CJ, Bonifazi A, Xi ZX (January 2021)."New Drugs, Old Targets: Tweaking the Dopamine System to Treat Psychostimulant Use Disorders".Annu Rev Pharmacol Toxicol.61:609–628.doi:10.1146/annurev-pharmtox-030220-124205.PMC 9341034.PMID 33411583.
  6. ^Lee KH, Fant AD, Guo J, Guan A, Jung J, Kudaibergenova M, Miranda WE, Ku T, Cao J, Wacker S, Duff HJ, Newman AH, Noskov SY, Shi L (September 2021)."Toward Reducing hERG Affinities for DAT Inhibitors with a Combined Machine Learning and Molecular Modeling Approach".J Chem Inf Model.61 (9):4266–4279.doi:10.1021/acs.jcim.1c00856.PMC 9593962.PMID 34420294.From this validation set of DAT inhibitors, we noticed that a pair of analogs with similar chemical structures, JJC8-01646 and JJC8-08813 (Tanimoto similarity = 0.62, Figure S6), have opposite trends of affinities at DAT and hERG. JJC8-088 has ~90-fold higher affinity than JJC8-016 at DAT (Ki = 2.6 and 234.4 nM, respectively), but has ~2-fold lower affinity than JJC8-016 at hERG (IC50 = 0.13 and 0.06 μM, respectively).
  7. ^Ku TC, Cao J, Won SJ, Guo J, Camacho-Hernandez GA, Okorom AV, Salomon KW, Lee KH, Loland CJ, Duff HJ, Shi L, Newman AH (February 2024)."Series of (([1,1'-Biphenyl]-2-yl)methyl)sulfinylalkyl Alicyclic Amines as Novel and High Affinity Atypical Dopamine Transporter Inhibitors with Reduced hERG Activity".ACS Pharmacol Transl Sci.7 (2):515–532.doi:10.1021/acsptsci.3c00322.PMC 10863442.PMID 38357284.
  8. ^Furutani K. Facilitation of hERG Activation by Its Blocker: A Mechanism to Reduce Drug-Induced Proarrhythmic Risk.Int. J. Mol. Sci. 2023; 24(22): 16261.doi:10.3390/ijms242216261
  9. ^Creanza TM, et al. Structure-Based Prediction of hERG-Related Cardiotoxicity: A Benchmark Study.J.Chem. Inf.Model. 2021; 61:4758−4770. {{doi:10.1021/acs.jcim.1c00744}}
Adamantanes
Adenosine antagonists
Alkylamines
Ampakines
Arylcyclohexylamines
Benzazepines
Cathinones
Cholinergics
Convulsants
Eugeroics
Oxazolines
Phenethylamines
Phenylmorpholines
Piperazines
Piperidines
Phenethylpyrrolidines
Racetams
Psychedelics
Tropanes
Tryptamines
Others
DATTooltip Dopamine transporter
(DRIsTooltip Dopamine reuptake inhibitors)
NETTooltip Norepinephrine transporter
(NRIsTooltip Norepinephrine reuptake inhibitors)
SERTTooltip Serotonin transporter
(SRIsTooltip Serotonin reuptake inhibitors)
VMATsTooltip Vesicular monoamine transporters
Others
σ1
σ2
Unsorted
Calcium
VDCCsTooltip Voltage-dependent calcium channels
Blockers
Activators
Potassium
VGKCsTooltip Voltage-gated potassium channels
Blockers
Activators
IRKsTooltip Inwardly rectifying potassium channel
Blockers
Activators
KCaTooltip Calcium-activated potassium channel
Blockers
Activators
K2PsTooltip Tandem pore domain potassium channel
Blockers
Activators
Sodium
VGSCsTooltip Voltage-gated sodium channels
Blockers
Activators
ENaCTooltip Epithelial sodium channel
Blockers
Activators
ASICsTooltip Acid-sensing ion channel
Blockers
Chloride
CaCCsTooltip Calcium-activated chloride channel
Blockers
Activators
CFTRTooltip Cystic fibrosis transmembrane conductance regulator
Blockers
Activators
Unsorted
Blockers
Others
TRPsTooltip Transient receptor potential channels
LGICsTooltip Ligand gated ion channels
Phenylpiperazines
Benzylpiperazines
Naphthylpiperazines
Quinolinylpiperazines
Diphenylalkylpiperazines
Pyrimidinylpiperazines
Pyridinylpiperazines
Benzo(iso)thiazolylpiperazines
Tricyclic-linked piperazines
Others/uncategorized
Retrieved from "https://en.wikipedia.org/w/index.php?title=JJC8-088&oldid=1320435842"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp